Insulin glargine benefits patients with type 2 diabetes inadequately controlled on oral antidiabetic treatment: an observational study of everyday practice in 12,216 patients
- 30 May 2006
- journal article
- clinical trial
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 9 (1), 31-38
- https://doi.org/10.1111/j.1463-1326.2006.00593.x
Abstract
This observational study aimed to investigate the long-term efficacy and safety of adding insulin glargine (LANTUS((R))) to support oral antidiabetic (OAD) treatment in patients with type 2 diabetes in everyday practice. A 9-month, open-label, multicentre, observational study, with an optional 20-month extension phase, in which add-on insulin glargine therapy was initiated in 12,216 patients with type 2 diabetes inadequately controlled on OADs. The insulin glargine dose was adjusted at the physician's discretion, reflecting everyday practice. The main outcome measures were changes in HbA(1c), fasting blood glucose (FBG), insulin dose and body mass index (BMI). At baseline, mean (+/- s.d.) age was 63.9 +/- 11.3 years; disease duration was >5 years in 47% of patients, 1-5 years in 39% of patients and <1 year in 10% of patients, while 4% of patients were newly diagnosed. Addition of insulin glargine to OAD therapy led to reductions in mean HbA(1c) (-1.5% from 8.7%) and FBG (-69 mg/dl from 202 mg/dl) levels after 3 months, which were maintained after 9 months [HbA(1c): -1.7%; FBG: -71 mg/dl (-3.9 mmol/l)] without an increase in BMI. Similar glycaemic control was observed after 20 months in the 2721 patients in the extension study. Adverse drug reactions were documented in 26 patients (0.2%). Of 47 adverse events documented, 19 were due to hypoglycaemia. In everyday practice, patients with type 2 diabetes who are inadequately controlled on OADs benefit from add-on basal insulin treatment with insulin glargine as they demonstrate improved glycaemic control without weight gain.Keywords
This publication has 20 references indexed in Scilit:
- Basal insulin supplementation in type 2 diabetes: refining the tacticsAmerican Journal Of Medicine, 2004
- Standards of Medical Care in DiabetesDiabetes Care, 2004
- A One-year, Randomised, Multicentre Trial Comparing Insulin Glargine with NPH Insulin in Combination with Oral Agents in Patients with Type 2 DiabetesHormone and Metabolic Research, 2003
- Issues relating to the early or earlier use of insulin in type 2 diabetesPractical Diabetes International, 2003
- Insulin GlargineDrugs, 2003
- Combination therapy with insulin and oral agents: optimizing glycemic control in patients with type 2 diabetes mellitusDiabetes/Metabolism Research and Reviews, 2002
- Randomized, Controlled Trials, Observational Studies, and the Hierarchy of Research DesignsNew England Journal of Medicine, 2000
- A Comparison of Observational Studies and Randomized, Controlled TrialsNew England Journal of Medicine, 2000
- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)The Lancet, 1998
- Relationship between lactate dehydrogenase and myeloperoxidase levels in human gingival crevicular fluid and clinical and microbial measurementsJournal of Clinical Periodontology, 1988